Phase 2b clinical trial for Sugardown

|By:, SA News Editor

Boston Therapeutics (BTHE) initiates a Phase 2b clinical trial to evaluate the safety and effectiveness of its dietary supplement Sugardown. The 24-patient five-week study will assess 4 g and 8 g doses of Sugardown versus placebo on glucose levels in patients with Type 2 diabetes treated with metformin as a monotherapy. The primary endpoint is postprandial serum glucose area under the curve.